Heron Therapeutics (NASDAQ:HRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “

A number of other research firms have also recently weighed in on HRTX. ValuEngine raised Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. BidaskClub raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 target price on shares of Heron Therapeutics in a research note on Monday, December 31st. Finally, Stifel Nicolaus initiated coverage on shares of Heron Therapeutics in a research note on Thursday, September 13th. They issued a “buy” rating and a $55.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. Heron Therapeutics presently has a consensus rating of “Buy” and an average price target of $52.09.

Shares of NASDAQ HRTX traded up $0.07 during midday trading on Wednesday, hitting $26.07. The company’s stock had a trading volume of 22,859 shares, compared to its average volume of 942,649. Heron Therapeutics has a 1-year low of $19.55 and a 1-year high of $42.90. The firm has a market capitalization of $1.98 billion, a PE ratio of 7.14 and a beta of 1.49.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The firm had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. During the same period in the previous year, the company posted ($0.77) EPS. The firm’s revenue for the quarter was up 130.9% compared to the same quarter last year. Equities research analysts expect that Heron Therapeutics will post -2.29 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its stake in Heron Therapeutics by 6.5% in the 2nd quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock valued at $438,654,000 after purchasing an additional 693,699 shares during the period. Vanguard Group Inc boosted its stake in Heron Therapeutics by 36.7% in the 3rd quarter. Vanguard Group Inc now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares during the period. Vanguard Group Inc. boosted its stake in Heron Therapeutics by 36.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares during the period. BlackRock Inc. boosted its stake in Heron Therapeutics by 5.2% in the 3rd quarter. BlackRock Inc. now owns 4,780,799 shares of the biotechnology company’s stock worth $151,313,000 after purchasing an additional 236,068 shares during the period. Finally, FIL Ltd boosted its stake in Heron Therapeutics by 3.5% in the 3rd quarter. FIL Ltd now owns 3,063,383 shares of the biotechnology company’s stock worth $96,956,000 after purchasing an additional 103,224 shares during the period.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.